MHC class II expression is differentially regulated in plasmacytoid and conventional dendritic cells

被引:0
|
作者
Salomé LeibundGut-Landmann
Jean-Marc Waldburger
Caetano Reis e Sousa
Hans Acha-Orbea
Walter Reith
机构
[1] University of Geneva Medical School,Department of Pathology and Immunology
[2] Immunobiology Laboratory,Department of Biochemistry
[3] Cancer Research UK,Division of Rheumatology
[4] London Research Institute,undefined
[5] Faculty of Biology and Medicine,undefined
[6] University of Lausanne,undefined
[7] University Hospital,undefined
来源
Nature Immunology | 2004年 / 5卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Major histocompatibility complex (MHC) class II–restricted antigen presentation is essential for the function of dendritic cells (DCs). We show here that plasmacytoid DCs (pDCs) differ from all other DC subsets with respect to expression of CIITA, the 'master regulator' of MHC class II genes. The gene encoding CIITA is controlled by three cell type–specific promoters: pI, pIII and pIV. With gene targeting in mice, we demonstrate that pDCs rely strictly on the B cell promoter pIII, whereas macrophages and all other DCs depend on pI. The molecular mechanisms driving MHC class II expression in pDCs are thus akin to those operating in lymphoid rather than myeloid cells.
引用
收藏
页码:899 / 908
页数:9
相关论文
共 50 条
  • [41] Role of PU.1 in MHC class II expression through transcriptional regulation of class II transactivator pI in dendritic cells
    Kitamura, Nao
    Yokoyama, Hokuto
    Yashiro, Takuya
    Nakano, Nobuhiro
    Nishiyama, Makoto
    Kanada, Shunsuke
    Fukai, Tatsuo
    Hara, Mutsuko
    Ikeda, Shigaku
    Ogawa, Hideoki
    Okumura, Ko
    Nishiyama, Chiharu
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 129 (03) : 814 - U319
  • [42] Developmental regulation of MHC class II transport in mouse dendritic cells
    Philippe Pierre
    Shannon J. Turley
    Evelina Gatti
    Michael Hull
    Joseph Meltzer
    Asra Mirza
    Kayo Inaba
    Ralph M. Steinman
    Ira Mellman
    Nature, 1997, 388 : 787 - 792
  • [43] DIFFERENTIAL MHC CLASS-II EXPRESSION ON HUMAN PERIPHERAL-BLOOD MONOCYTES AND DENDRITIC CELLS
    BROOKS, CF
    MOORE, M
    IMMUNOLOGY, 1988, 63 (02) : 303 - 311
  • [44] EBV promotes IFN-Alpha production by plasmacytoid dendritic cells through MHC class II molecules and TLR-9.
    Quan, Timothy E.
    Roman, Robert R.
    Rudenga, Benjamin
    Holers, V. Michael
    Craft, Joseph E.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S42 - S42
  • [45] Differentially expressed microRNAs regulate plasmacytoid vs conventional dendritic cell development
    Kuipers, Harmjan
    Schnorfeil, Frauke M.
    Brocker, Thomas
    MOLECULAR IMMUNOLOGY, 2010, 48 (1-3) : 333 - 340
  • [46] Anti-tumor effects of dendritic and tumor cell fusions are not dependent on expression of MHC class I and II by dendritic cells
    Takagi, Y
    Kikuchi, T
    Niimura, M
    Ohno, T
    CANCER LETTERS, 2004, 213 (01) : 49 - 55
  • [47] Regulation of MHC class II expression in glioma cells by class II transactivator (CIITA)
    Takamura, Y
    Ikeda, H
    Kanaseki, T
    Toyota, M
    Tokino, T
    Imai, K
    Houkin, K
    Sato, N
    GLIA, 2004, 45 (04) : 392 - 405
  • [48] Interleukin-10 differentially modulates MHC class II expression by mesangial cells and macrophages in vitro and in vivo
    Chadban, SJ
    Tesch, GH
    Foti, R
    Lan, HY
    Atkins, RC
    Nikolic-Paterson, DJ
    IMMUNOLOGY, 1998, 94 (01) : 72 - 78
  • [49] Ligation of MHC class II molecules differentially upregulates TNFβ gene expression in B cell lines of different MHC class II haplotypes
    Guo, WY
    Mourad, W
    Charron, D
    Al-Daccak, R
    HUMAN IMMUNOLOGY, 1999, 60 (04) : 312 - 322
  • [50] Auranofin, an immunosuppressive drug, inhibits MHC class I and MHC class II pathways of antigen presentation in dendritic cells
    Han, Shinha
    Kim, Kwanghee
    Song, Youngcheon
    Kim, Hyunyul
    Kwon, Jeunghak
    Lee, Young-Hee
    Lee, Chong-Kil
    Lee, Sang-Jin
    Ha, Namjoo
    Kim, Kyungjae
    ARCHIVES OF PHARMACAL RESEARCH, 2008, 31 (03) : 370 - 376